(0.08%) 5 252.57 points
(0.04%) 39 776 points
(-0.11%) 16 381 points
(2.00%) $82.98
(1.28%) $1.740
(1.30%) $2 241.50
(0.97%) $24.99
(1.37%) $922.15
(0.28%) $0.926
(0.71%) $10.84
(0.09%) $0.792
(0.14%) $92.57
Live Chart Being Loaded With Signals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...
Stats | |
---|---|
Today's Volume | 97 758.00 |
Average Volume | 117 920 |
Market Cap | 145.97B |
EPS | €0 ( 2024-01-30 ) |
Next earnings date | ( €0 ) 2024-04-29 |
Last Dividend | €0.410 ( 2023-07-27 ) |
Next Dividend | €0 ( N/A ) |
P/E | 76.03 |
ATR14 | €0.0360 (0.14%) |
Volume Correlation
Pfizer Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pfizer Inc Correlation - Currency/Commodity
Pfizer Inc Financials
Annual | 2023 |
Revenue: | €58.50B |
Gross Profit: | €33.54B (57.34 %) |
EPS: | €0.380 |
Q4 | 2023 |
Revenue: | €14.25B |
Gross Profit: | €1.14B (7.97 %) |
EPS: | €-0.600 |
Q3 | 2023 |
Revenue: | €13.23B |
Gross Profit: | €3.96B (29.95 %) |
EPS: | €-0.420 |
Q2 | 2023 |
Revenue: | €12.73B |
Gross Profit: | €9.50B (74.58 %) |
EPS: | €0.410 |
Financial Reports:
No articles found.
Pfizer Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.400 (N/A) |
€0.400 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.410 | 2023-07-27 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 68 | -- |
Total Paid Out | €20.64 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.69 | -- |
Div. Sustainability Score | 6.07 | |
Div.Growth Potential Score | 4.01 | |
Div. Directional Score | 5.04 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SOBA.DE | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
DTE.DE | Ex Dividend Junior | 2023-04-06 | Annually | 0 | 0.00% | |
LUS1.F | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
AEIN.DE | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
UN9.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
FMC1.DE | Ex Dividend Knight | 2023-07-24 | Semi-Annually | 0 | 0.00% | |
NTH.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
BEI.DE | Ex Dividend Knight | 2023-04-14 | Annually | 0 | 0.00% | |
XTP.F | No Dividend Player | 2023-05-12 | Sporadic | 0 | 0.00% | |
HBH.DE | Ex Dividend Junior | 2023-07-10 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0367 | 1.500 | 9.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00947 | 1.200 | 9.68 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0222 | 1.500 | -0.864 | -1.296 | [0.1 - 1] |
payoutRatioTTM | 4.31 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.907 | 0.800 | -0.467 | -0.373 | [1 - 3] |
quickRatioTTM | 0.583 | 0.800 | -1.279 | -1.023 | [0.8 - 2.5] |
cashRatioTTM | 0.0597 | 1.500 | -0.779 | -1.169 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.18 | [0 - 0.6] |
interestCoverageTTM | 0.551 | 1.000 | -0.907 | -0.907 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.57 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.796 | -1.500 | 6.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.479 | 1.000 | 5.36 | 5.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0208 | 1.000 | -1.584 | -1.584 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.123 | 1.000 | -0.429 | -0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.258 | 0.800 | -1.612 | -1.289 | [0.5 - 2] |
Total Score | 6.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 72.71 | 1.000 | 2.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0222 | 2.50 | -0.555 | -1.296 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.71 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 5.92 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 4.31 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -2.59 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.149 | 1.000 | 8.78 | 0 | [0.1 - 0.5] |
Total Score | 4.01 |
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators